利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

3 条记录 (耗时 0.011 秒)

    TREATMENT OF PENETRATIVE INJURY TO THE BRAIN
    2.
    发明公开
    TREATMENT OF PENETRATIVE INJURY TO THE BRAIN 有权
    BEHANDLUNG VONSCHÄDIGUNGENDES GEHIRNS DURCH EINDRINGUNGEN

    公开(公告)号：EP2616094A2

    公开(公告)日：2013-07-24

    申请号：EP11817146.1

    申请日：2011-08-12

    申请人： NoNO Inc.

    发明人： TYMIANSKI, Michael ,  LU, Peter S. ,  GARMAN, Johathan David

    IPC分类号： A61K38/16 ,  A61K38/08 ,  A61K38/10 ,  A61P25/00

    CPC分类号： A61K38/07 ,  A61K38/08 ,  A61K38/1709 ,  A61K38/1787 ,  A61K47/645 ,  C07K7/06 ,  C07K2319/10 ,  C12N9/0075 ,  C12Y114/13039 ,  G01N33/573 ,  G01N33/6872 ,  G01N2333/70571 ,  G01N2333/90254 ,  G01N2500/02

    摘要： The invention provides methods of treatment or prophylaxis of damaging effects of penetrative injury to the brain or other part of the central nervous system. The methods are based in part on results in a rodent model of penetrative ballistic injury showing that an inhibitor of PDF-95 NMDAR interaction is effective in inhibiting neurological deficits resulting from such injury. The methods are useful for treating subjects having or at risk of penetrative brain injury, including subjects who have been shot in the head or at risk of such injury (e.g., military or law enforcement personnel).

    摘要翻译： 本发明提供治疗或预防渗透性损伤对脑或中枢神经系统其他部分的损伤作用的方法。 该方法部分基于穿透性弹道损伤啮齿动物模型的结果，表明PDF-95 NMDAR相互作用的抑制剂有效抑制由此类损伤引起的神经功能缺损。 这些方法对于治疗具有或具有渗透性脑损伤风险的受试者是有用的，包括头部受到攻击或有受此风险的受试者（例如军事或执法人员）。

    AGENTS AND METHODS FOR TREATMENT OF PAIN
    3.
    发明公开
    AGENTS AND METHODS FOR TREATMENT OF PAIN 审中-公开
    手段和治疗疼痛的方法

    公开(公告)号：EP2334315A2

    公开(公告)日：2011-06-22

    申请号：EP09812187.4

    申请日：2009-09-02

    申请人： Arbor Vita Corporation ,  Nono, Inc.

    发明人： BELMARES, Michael P. ,  GARMAN, J. David ,  LU, Peter S. ,  SALTER, Michael W. ,  TYMIANSKI, Michael

    IPC分类号： A61K38/00

    CPC分类号： C07K7/08 ,  A61K38/08 ,  A61K38/10 ,  C07K7/06

    摘要： The invention provides agents useful for treating pain. An exemplary agent comprises or consists of the a portion of a retroviral Tat protein. One such agent is the peptide Tat-NR2B9c. This peptide has previously been described as an agent for inhibiting damaging effects of stroke and similar conditions via inhibition of PSD95 interactions with NMDA receptors and/or NOS. The present application provides data showing that the Tat-NR2B9c peptides is effective in alleviation of pain. The alleviation of pain can be obtained at a dose of the peptide below the dose required to inhibit PSD-95 interactions with NMDAR or NOS.